Amy E. Tapper Ph.D.
Net Worth
Last updated:
What is Amy E. Tapper Ph.D. net worth?
The estimated net worth of Dr. Amy E. Tapper Ph.D. is at least $9,577,769 as of 3 Jan 2023. He owns shares worth $4,286,882 as insider, has earned $4,234,647 from insider trading and has received compensation worth at least $1,056,240 in Imago BioSciences, Inc..
What is the salary of Amy E. Tapper Ph.D.?
Dr. Amy E. Tapper Ph.D. salary is $352,080 per year as Senior Vice President of Chemistry, Manufacturing & Controls and Non-Clinical Devel. in Imago BioSciences, Inc..
How old is Amy E. Tapper Ph.D.?
Dr. Amy E. Tapper Ph.D. is 54 years old, born in 1971.
What stocks does Amy E. Tapper Ph.D. currently own?
As insider, Dr. Amy E. Tapper Ph.D. owns shares in one company:
Company | Title | Shares | Price per share | Total value |
---|---|---|---|---|
Imago BioSciences, Inc. (IMGO) | Senior Vice President of Chemistry, Manufacturing & Controls and Non-Clinical Devel. | 119,047 | $36.01 | $4,286,882 |
What does Imago BioSciences, Inc. do?
Imago BioSciences, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms chronic cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Amy E. Tapper Ph.D. insider trading
Imago BioSciences, Inc.
Dr. Amy E. Tapper Ph.D. has made 10 insider trades between 2022-2023, according to the Form 4 filled with the SEC.
The largest trade he's ever made was exercising 100,302 units of IMGO stock on 16 Dec 2022. As of 3 Jan 2023 he still owns at least 119,047 units of IMGO stock.
Imago BioSciences key executives
Imago BioSciences, Inc. executives and other stock owners filed with the SEC:
- Dr. Amy E. Tapper Ph.D. (54) Senior Vice President of Chemistry, Manufacturing & Controls and Non-Clinical Devel.
- Dr. Hugh Young Rienhoff Jr. (72) Chief Executive Officer & Director
- Ms. Jennifer Peppe (54) Senior Vice President of Clinical Operations